Emergent BioSolutions Inc. (NYSE:EBS) announced that it has signed a new, multi-year, firm fixed price contract with the U.S. Department of Health and Human Services (HHS) to supply an additional 14.5 million doses of BioThrax(R) (Anthrax Vaccine Adsorbed), its FDA licensed anthrax vaccine, for inclusion in the Strategic National Stockpile (SNS).
The total value of this follow-on contract is between $364 million and $404 million, with the higher amount tied to the delivery of product having four-year expiry dating.
First deliveries of BioThrax under this new contract are scheduled to begin in 3Q 2009, immediately following the scheduled completion of deliveries under the company’s current $448 million contract to supply 18.75 million doses of BioThrax to the SNS. Final product deliveries under this new contract are anticipated in 3Q 2011.
“This follow-on contract with HHS is continuing evidence of the government’s steadfast commitment to procure critical countermeasures to protect against the threat of bioterrorism in our country,” said Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions. “We are encouraged that we were able to secure this new procurement for an additional 14.5 million doses with HHS, because it represents a seamless transition from our current contract for the shipment of 18.75 million doses of BioThrax into the SNS. This clearly demonstrates the U.S. government’s commitment to maintaining a strong, domestic industrial base for biodefense medical countermeasures.”
Source: Emergent BioSolutions Inc., USA